Compare VRRM & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRRM | ZYME |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | United States |
| Employees | N/A | 264 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2016 | 2022 |
| Metric | VRRM | ZYME |
|---|---|---|
| Price | $4.67 | $22.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $25.90 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 10.7M | 610.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 347.37 | 33.33 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $132,969,000.00 | $105,965,000.00 |
| Revenue This Year | $6.84 | $183.10 |
| Revenue Next Year | $6.88 | N/A |
| P/E Ratio | $26.47 | ★ N/A |
| Revenue Growth | 14.61 | ★ 38.87 |
| 52 Week Low | $3.40 | $11.86 |
| 52 Week High | $25.83 | $29.75 |
| Indicator | VRRM | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 23.47 | 36.59 |
| Support Level | $3.40 | $22.28 |
| Resistance Level | $25.10 | $23.66 |
| Average True Range (ATR) | 0.53 | 0.92 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 12.71 | 17.07 |
Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe, and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three reportable segments: Commercial Services, Government Solutions, and Parking Solutions. Maximum revenue is generated from the Commercial Services segment, which offers toll and violation management solutions and title and registration services for commercial fleet customers, including RACs and FMCs in North America. In Europe, it provides tolling and violations processing services.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.